含有甲基部分的异库玛林作为异形选择性瘤相关碳酸酶抑制剂起作用
Mehmet Onyilmaz1, Murat Koca2, Andrea Ammara3
1Faculty of Science & Arts, Department of Chemistry, Harran University, Sanliurfa 63290, Turkey.
Future medicinal chemistry
|August 7, 2024
概括
新的异黄-混杂物显示出与瘤相关的碳酸无水酶 (hCA IX和XII) 抑制剂的潜力,对其他形式的影响最小. 这一发现为新的癌症疗法提供了潜力.
科学领域:
- 药用化学 医学化学
- 生物化学 生物化学
- 酶抑制可以抑制酶.
背景情况:
- 人类碳酸无水酶 (hCA) 是参与各种生理过程的关键酶.
- 异常的hCA活性,特别是与瘤相关的异型,如hCA IX和XII,与癌症进展有关.
- 开发针对这些瘤相关异型的选择性抑制剂是关键的治疗策略.
研究的目的:
- 合成和评估一系列新型的异黄-混杂物,作为人类碳酸酶异型的潜在抑制剂.
- 评估对细胞系 (hCA I,II) 和与瘤相关的 (hCA IX,XII) 异型的抑制活性.
- 探索一种新的化学支架,用于开发向癌症治疗方法.
主要方法:
- 异黄-混杂物是通过将乙异黄与各种芳香性化物凝结合成的.
- 进行了酶抑制试验,以确定针对纯化hCA I,II,IX和XII的抑制常数 (KI).
- 基于抑制性数据,分析了结构-活性关系.
主要成果:
- 合成的异素-化混合体对异细胞异型hCA I和II (KI> > 100μM) 的弱抑制.
- 这些化合物对与瘤相关的异型hCA IX和XII有强烈的抑制作用,抑制常数在低微分子到亚微分子范围内.
- 这种新型化学型在向与癌症相关的碳酸化酶异型时被证明是有效的.
结论:
- 异库马林-化混合物代表了瘤相关碳酸无水酶 (hCA IX和XII) 抑制剂的有前途的新类.
- 对瘤相关异构体的选择性相对于细胞质异构体的选择性表明一种有利的治疗特征.
- 这项研究为进一步开发这些化合物作为潜在的抗癌剂提供了基础,补充了诸如硫胺SLC-0111.等现有策略.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Molecules with Multiple Chiral Centers
11.4K
Molecules that possess multiple chiral centers can afford a large number of stereoisomers. For instance, while some molecules like 2-butanol have one chiral center, defined as a tetrahedral carbon atom with four different substituents attached, several molecules like butane-2,3-diol have multiple chiral centers. A simple formula to predict the number of stereoisomers possible for a molecule with n chiral centers is 2n. However, there can be a lower number where some of the stereoisomers are...
11.4K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
548
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
548
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Carboxylic Acid Derivatives: Overview
3.5K
Carboxylic acid derivatives are formed by replacing the hydroxyl group of carboxylic acids with a different functional group. The most common carboxylic acid derivatives are:
3.5K
Prochirality
3.8K
The concept of prochirality leads to the nomenclature of the individual faces of a molecule and plays a crucial role in the enantioselective reaction. It is a concept where two or more achiral molecules react to produce chiral products. A typical process is the reaction of an achiral ketone to generate a chiral alcohol. Here, the achiral reactant reacts with an achiral reducing agent, sodium borohydride, to generate an equimolar mixture of the chiral enantiomers of the product. For example, an...
3.8K


